POLBF
Poolbeg Pharma PLC
Set alert
- YTD
- +125.41%
- 1 year
- +125.41%
- Open
- 0.095
- Prev close
- 0.0958
- Mkt cap
- 67.55M
- Vol
- 10.00K
- Avg vol
- 78
- EPS
- -0.01
- P/E
- 0.00
More statistics
- Low
- 0.095
- High
- 0.095
News
3 weeks ago proactiveinvestors.com
Poolbeg Pharma's Korean patent grant bolsters Cavendish's ‘buy' case
Poolbeg Pharma PLC (AIM:POLB) secured a South Korean patent for POLB 001, with Cavendish retaining its ‘buy' rating and unchanged 19.0 pence target, citing potential partnering benefits. The patent…
3 weeks ago proactiveinvestors.com
Poolbeg secures South Korean cancer immunotherapy-induced CRS patent
Poolbeg Pharma PLC (AIM:POLB), the clinical-stage biopharmaceutical company, has secured a South Korean patent for POLB 001 to prevent cytokine release syndrome (CRS) induced by cancer immunotherapy.…
1 month ago proactiveinvestors.com
Poolbeg Pharma retains ‘buy' rating at Cavendish after safety review allows trial to continue
Cavendish, the City broker, has kept its ‘buy' rating on biopharmaceutical company Poolbeg Pharma PLC (AIM:POLB) after a positive safety review allowed its lead drug, POLB 001, to continue without…
1 month ago proactiveinvestors.com
Poolbeg Pharma funded to finish both trials as it courts partners for cancer drug
Poolbeg Pharma PLC (AIM:POLB) says both of its clinical programmes are now funded through to completion, with cash expected to last into the second quarter of 2028. The focus for the rest of the year…
1 month ago proactiveinvestors.com
Poolbeg Pharma doses eight patients in cancer side-effect trial
Poolbeg Pharma PLC (AIM:POLB) has dosed eight patients in its TOPICAL trial, which is testing whether its drug POLB 001 can prevent a dangerous side effect of cancer immunotherapy. The trial aims to…
1 month ago seekingalpha.com
Poolbeg Pharma PLC (POLBF) Shareholder/Analyst Call Transcript
Poolbeg Pharma PLC (POLBF) Shareholder/Analyst Call Transcript
1 month ago proactiveinvestors.com
Poolbeg Pharma trial progress strengthens Cavendish case for 19p target
Poolbeg Pharma PLC's (AIM:POLB) lead clinical programme has reached another milestone after an interim safety review cleared its TOPICAL trial to continue without changes, prompting Cavendish to…
1 month ago proactiveinvestors.com
Poolbeg Pharma gets green light to continue clinical trial
Poolbeg Pharma PLC (AIM:POLB) told investors that its POLB 001 TOPICAL clinical trial will continue as planned after an interim safety review recommended no changes to the study protocol. Patient…
3 months ago proactiveinvestors.co.uk
Poolbeg wins Israeli patent nod for lead cancer immunotherapy drug
Poolbeg Pharma PLC (AIM:POLB) has secured a Notice of Allowance from the Israeli Patent Office for its POLB 001 cancer immunotherapy-induced cytokine release syndrome patent application. The…
3 months ago proactiveinvestors.co.uk
Poolbeg Pharma raises £3.5m to support key trial and GLP-1 progress
Poolbeg Pharma PLC (AIM:POLB), the clinical-stage biopharmaceutical, has raised £3.5 million before expenses through a share placing. Cathal Friel, executive chair, subscribed for £250,000 of the…
3 months ago proactiveinvestors.co.uk
Cavendish sees multi-billion-dollar prize as Poolbeg begins pivotal trial
Cavendish has reiterated its 'buy' rating on Poolbeg Pharma PLC (AIM:POLB), arguing that the drug developer's first patient dosing marks the start of a value-creating period for the shares. The…
3 months ago proactiveinvestors.co.uk
Poolbeg doses first patient in cancer immunotherapy safety trial
Poolbeg Pharma PLC (AIM:POLB), a clinical-stage biopharmaceutical company focused on cancer immunotherapy, has dosed the first patient in its POLB 001 TOPICAL clinical trial. The AIM-listed company…
4 months ago proactiveinvestors.co.uk
Poolbeg Pharma secures South African patent for lead drug candidate
Poolbeg Pharma PLC (AIM:POLB), the biopharmaceutical company focused on cancer immunotherapy, said it had been granted a patent in South Africa for its lead drug candidate, POLB 001. The patent…
4 months ago proactiveinvestors.co.uk
Poolbeg's European patent win bolsters partnering case before summer trial data, says Cavendish
Shares in PPoolbeg Pharma PLC (AIM:POLB) rose 3% to 7.8p on Tuesday, taking their gain for the year to date to around 100%, after the drug developer secured a key European patent. The European Patent…
4 months ago proactiveinvestors.co.uk
European patent boosts Poolbeg Pharma's POLB 001 IP portfolio
Poolbeg Pharma PLC (AIM:POLB), the clinical-stage biopharmaceutical company, has been granted a European patent for its POLB 001 treatment in cancer immunotherapy-induced cytokine release syndrome…
4 months ago proactiveinvestors.co.uk
Poolbeg Pharma has begun an exciting new clinical trial - ICYMI
Poolbeg Pharma PLC (AIM:POLB) this week announced the activation of clinical trial sites for its POLB 001 programme, marking the start of patient enrolment in a study designed to prevent cytokine…
4 months ago proactiveinvestors.co.uk
Poolbeg Pharma shows clinical progress with latest updates
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF) said it has activated the first clinical site for its first-in-patient POLB 001 TOPICAL trial, moving its lead cancer immunotherapy programme into…
5 months ago proactiveinvestors.com
Cavendish says FDA alignment de-risks Poolbeg Pharma's lead cancer therapy programme for partners
Shares Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the clinical-stage biopharmaceutical company, were up 9% following the positive outcome of a...
5 months ago proactiveinvestors.co.uk
Cavendish says FDA alignment de-risks Poolbeg Pharma's lead cancer therapy programme for partners
Shares Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the clinical-stage biopharmaceutical company, were up 9% following the positive outcome of a pre-investigational new drug meeting with the…
5 months ago proactiveinvestors.co.uk
Poolbeg Pharma gets positive FDA feedback for development pathway of lead cancer therapy asset
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF), the clinical-stage biopharmaceutical company, has received positive feedback from the US Food and Drug Administration (FDA) in a…